PAROXETINE HYDROCHLORIDE | N020031 | APOTEX INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Lachman Consulting Services, Inc. FDA-2023-P-4289 Lachman Consulting Services, Inc. submitted this suitability petition on behalf of a client requesting that the FDA declare Paroxetine Orally Disintegrating Tablets in 10 mg, 20 mg, 30 mg, and 40 mg strengths suitable for submission in an ANDA under Section 505(j)(2)(C) of the FDC Act, with the refe | Suitability | 2023-10-03 | Open | Lachman Consulting Services |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.